Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

64.31 -0.98 (-1.50%)
Official Closing Price Updated: 7:00 PM EDT, Jul 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
85 86 Next >
Novo Nordisk Slashes Wegovy Price, Undercutting Hims & Hers Health
The news slammed Hims stock. Hims & Hers sells knockoff versions of semaglutide, the chemical backbone behind Wegovy. 
Via Investor's Business Daily
Down 39%. Is Novo Nordisk Stock a Buy on the Dip?
Via The Motley Fool
Investors should take note of NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO), a growth stock that remains attractively priced.
Uncover the potential of NOVO-NORDISK A/S-SPONS ADR, a growth stock reasonably priced. NYSE:NVO is excelling in growth aspects, maintaining a healthy financial position, and still offers an attractive... 
Via Chartmill
$1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against TELUS International, Novo Nordisk, Micron, and ModivCare and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Why Novo Nordisk Stock Popped on Friday
Via The Motley Fool
AbbVie Becomes Another Big Pharma To Enter Obesity Treatment Race
AbbVie partners with Gubra in a $2.2 billion deal to develop GUB014295, an amylin analog for obesity. The move marks AbbVie's entry into the competitive weight-loss market. 
Via Benzinga
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
From Faruqi & Faruqi LLP
Via GlobeNewswire
AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.
This is the drugmaker's first foray into weight-loss drugs. And it's not focusing on GLP-1. 
Via Investor's Business Daily
NOVO NORDISK A/S (NYSE: NVO) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Novo Nordisk A/S Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVO
From The Rosen Law Firm PA
Via GlobeNewswire
Lowey Dannenberg Notifies Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
Behind Hims Stock's Roller-Coaster Ride As Weight-Loss Drugs Battle Heats Up
Can Hims & Hers Health recover after the FDA removed semaglutide from its drugs shortage list? 
Via Investor's Business Daily
Prediction: Novo Nordisk Will Soar Over the Next 5 Years. Here's 1 Reason Why.
Via The Motley Fool
Regeneron: Is It the Perfect Biotech Stock for Value and Growth?
Regeneron is trading at historically low valuations as its Dupixent blockbuster drug could get a 30% increase in TAM if the FDA approves its use in COPD. 
Via MarketBeat
Why Hims & Hers Stock Rebounded on Wednesday
Via The Motley Fool
6 Stocks to Buy as European Markets Soar
Via Benzinga
Novo Nordisk's Ozempic And Wegovy No Longer on FDA Shortage List, Faces Lawsuit Over Decision
A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms patients who rely on compounded versions of the drug. 
Via Benzinga
Topics Lawsuit
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
From Faruqi & Faruqi LLP
Via GlobeNewswire
Wall Street’s Most Wanted: 2 Highly Shorted Stocks Right Now
See why these two high-flying stocks are among the most shorted in the market, plus counterarguments amid bearish gripes. 
Via MarketBeat
Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?
Viking Therapeutics stock jumped on rumors of a potential acquirer looking to add a GLP-1 treatment to their portfolio and VK2735 appears to rival Zepbound. 
Via MarketBeat
Ranked: 10 Largest Companies In The U.S., Europe, And China
The top nine American companies by market cap are all worth more than a trillion dollars. 
Via Talk Markets
Topics Stocks / Equities
NOVO NORDISK A/S (NYSE: NVO) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Novo Nordisk A/S Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cardlytics, Novo Nordisk, Micron, and ModivCare and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
What To Expect When IBD 50's No. 2, Hims & Hers, Reports Amid The Semaglutide Battle
Hims & Hers Health is on deck to report its fourth-quarter earnings late Monday. Here's what to expect. 
Via Investor's Business Daily
Wall Street Thinks This Weight-Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk
Via The Motley Fool
Trump Reportedly Warns Big Pharma: Move Manufacturing To US Or Face Tariffs
President Donald Trump has issued a stringent warning to pharmaceutical companies, advising them to repatriate their manufacturing to the US or face the possibility of tariffs. 
Via Benzinga
Topics Government
Prediction: These Could Be the Best-Performing Value Stocks Through 2030
These two stocks are poised to crush the market thanks to their outsize growth prospects and dirt cheap valuations. 
Via The Motley Fool
ROSEN, A RESPECTED AND LEADING FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVO
From The Rosen Law Firm PA
Via GlobeNewswire
Pfizer Discontinues Hemophilia Gene Therapy Beqvez As Interest Wanes
Pfizer has discontinued Beqvez for hemophilia B due to low patient demand and will focus on alternative treatments, including its approved therapy, Hympavzi. 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
85 86 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.